INTRODUCTION
============

Contemporary risk-based therapy for childhood cancer has resulted in 5-year survival rates that now exceed 80%^[@B1]^; increasing attention, therefore, is being focused on the health and well-being of the growing population of long-term survivors.^[@B2]^ Treatment-related chronic health conditions are well described in this population and include vital organ compromise,^[@B3]--[@B9]^ endocrine disturbances,^[@B10]--[@B12]^ neurocognitive impairment,^[@B13]--[@B15]^ issues related to fertility and reproduction,^[@B16]--[@B18]^ and subsequent malignant neoplasms^[@B19]--[@B23]^; the cumulative incidence of severe or life-threatening chronic health conditions approaches 40% by 30 years from diagnosis.^[@B24]^

Because many chronic health conditions do not become clinically apparent for years after therapeutic exposure, ongoing risk-based care for survivors of childhood cancer is imperative.^[@B25]--[@B27]^ Specialized long-term follow-up (LTFU) programs have been established at many pediatric oncology centers to provide survivors with risk-directed care aimed at decreasing morbidity and mortality through targeted health promotion, early identification of therapy-related complications, and timely interventions to ameliorate those complications.^[@B25],[@B28],[@B29]^ These programs rely on LTFU guidelines,^[@B30]--[@B32]^ including the Children\'s Oncology Group (COG) Long-Term Follow-Up Guidelines,^[@B33],[@B34]^ to direct provision of risk-based survivorship care. The COG guidelines are accompanied by lay educational materials (Health Links)^[@B35]^ to inform survivors of exposure-specific health risks and promote health-protective behaviors.

Previous studies to evaluate adult survivors of childhood cancer have identified significant knowledge deficits,^[@B36]--[@B38]^ and only 35% of survivors have acknowledged that past therapies could cause serious health problems.^[@B36]^ Survivors who lack awareness about their health risks may fail to seek adequate follow-up care. Therefore, a major focus of specialized LTFU programs has been to improve awareness of risk for chronic health conditions in survivors. Physicians and nurses in these specialized LTFU programs typically provide education to survivors about their treatment history and health risks.^[@B39]--[@B42]^ However, the impact of specialized education provided in these programs on survivors\' awareness of their personal health risks is unclear. The current study addressed this gap in knowledge by assessing the trajectory of change in survivors\' awareness of personal risk for developing therapy-related complications after receipt of targeted education at up to five survivorship clinic visits; predictors of those who lacked risk awareness were also examined.

METHODS
=======

Study Participants
------------------

Participants were enrolled in the survivorship clinic at a single institution between December 2005 and September 2013. Eligibility for clinic participation included a diagnosis of cancer at age 21 or younger, in remission, and off cancer therapy for at least 2 years. Institutional review board approval for the study was obtained; all participants and/or their parents provided informed consent/assent.

Health Knowledge Questionnaire
------------------------------

Patients were eligible if they completed a health knowledge questionnaire at their initial survivorship clinic visit and had not previously attended any specialized LTFU program. Thus, questionnaire completion occurred before provision of any tailored education by the clinician at the baseline visit (T0) and at up to five subsequent LTFU visits (T1 through T5; Data Supplement). To accurately evaluate change in awareness of personal therapy-related health risks over time, and to ensure that the individual who completed the questionnaire was present for all teaching, questionnaires completed by individuals other than the baseline respondent were excluded from the analysis at subsequent time points. The questionnaire, available in both English and Spanish, consisted of 19 items that assessed the survivors\' knowledge of their cancer therapy and awareness of therapy-related health risks. For this analysis, we focused on the following item: "Have you ever been told that you might experience any of the following problems as a result of the treatment that you received for this illness?" Potential therapy-related complications were listed with the response choices yes, no, or don\'t know. At-risk patients who answered yes were categorized as aware; those who answered no or don\'t know were categorized as lacking awareness. For survivors younger than 13 years or those with cognitive impairment, the questionnaire was completed by the survivor\'s parent/caregiver; survivors between 13 and 15 years completed the questionnaire with assistance from their parent/caregiver; survivors 16 years or older completed the questionnaire independently.

Tailored Health Education
-------------------------

After completion of the questionnaire at each LTFU clinic visit, a nurse practitioner or physician provided education tailored to the survivor\'s personal risk for therapy-related late effects per the COG-LTFU Guidelines. Tailored education included a review of the patient\'s cancer treatment summary (Data Supplement) and followed a structured format guided by personalized teaching materials that contained simplified health promotion messages derived from and corresponding to the COG Health Links.^[@B35]^ Teaching materials used for each survivorship clinic visit were customized to individual survivors on the basis of age, sex, and therapeutic exposures. Study clinicians were involved in initial development and implementation of the materials or were trained in their standardized application upon joining the study team. Tailored materials were provided to clinicians by the research assistant, which prompted consistent use. Several strategies previously shown to enhance comprehension of patient education materials^[@B43]--[@B45]^ were incorporated into the design; these included organization of recommendations by body system, use of simplified fonts and bulleted lists, personalization, use of visual cues (icons) to introduce each topic, use of the second person (you) throughout, and preparation/presentation of materials in the survivor\'s preferred language (Data Supplement).

Main Outcome Measure: Awareness of Health Risks
-----------------------------------------------

Therapeutic exposures were abstracted from medical records. Exposure-related health risks were determined according to an algorithm that was based on the COG-LTFU Guidelines.^[@B33]^ For example, survivors who received anthracycline chemotherapy were categorized as at risk for both cardiac dysfunction and subsequent malignant neoplasms, because the COG-LTFU Guidelines specify an association between anthracyclines and each of these complications (Data Supplement).^[@B34]^ Each survivor\'s responses regarding their awareness of health risks were compared with their actual exposure-related health risks for nine therapy-related complications that are highly prevalent and/or associated with potentially serious health consequences (ie, cardiac dysfunction, pulmonary compromise, neurocognitive impairment, low bone mineral density, sensory impairment, renal impairment, thyroid problems, fertility problems, and subsequent malignant neoplasms).^[@B24],[@B46],[@B47]^ Awareness was defined as the proportion of personal risk of all complications correctly identified by the survivor at each time point.

Statistical Analyses
--------------------

Descriptive statistics were used to summarize demographic and clinical characteristics of study participants, knowledge of their therapeutic exposures, and awareness of personal risk for therapy-related complications (ie, proportion correct). Generalized estimating equations were used to examine overall awareness of personal health risks (ie, proportion of personal risk correctly identified for all at-risk complications). Survivors were classified into three groups (lowest, middle, and highest tertile of awareness) according to their overall level of awareness of risk for therapy-related complications at T0. Logistic regression was used to determine clinical and sociodemographic predictors (ie, diagnosis, sex, race/ethnicity, language, age at diagnosis and at study entry, time from diagnosis, educational level, number of at-risk complications) of low awareness (ie, being in the lowest tertile of awareness). Data were analyzed with SAS (SAS Institute, Cary, NC), version 9.3.

RESULTS
=======

Participant Characteristics
---------------------------

Three hundred sixty-nine patients met eligibility criteria for the study ([Table 1](#T1){ref-type="table"}) and completed a total of 1,248 clinic visits; the median age at diagnosis was 11 years (range, 0 to 21 years); the median age at study entry was 24 years (range, 5 to 57 years). Overall, 53% were male, 38% were non-Hispanic white, and 45% had a diagnosis of leukemia. The median time between two consecutive visits was 1 year (Data Supplement); all patients who completed the questionnaire at each time point had completed all prior time points (ie, there were no missing education visits). Participants at T1, T2, T3, and T4 were older at diagnosis and study entry than nonparticipants at these time points; time from diagnosis was longer for participants than nonparticipants at T4 only. There was no substantial difference in participant characteristics and no statistically significant difference in change in awareness between patients who did and did not complete T5 (Data Supplement).

###### 

Participant Characteristics at Baseline

![](zlj03315-5598-t01)

  Characteristic                                                                           No. (%) of Patients   *P*                                 
  ---------------------------------------------------------------------------------------- --------------------- ----------------- ----------------- ------
  Total patients                                                                           369 (100.0)           233 (63.1)        136 (36.9)        NA
  Male sex                                                                                 195 (52.9)            123 (52.8)        72 (52.9)         .98
  Diagnosis                                                                                                                                          
      Leukemia                                                                             165 (44.7)            93 (39.9)         72 (52.9)         .05
      Lymphoma                                                                             90 (24.4)             61 (26.2)         29 (21.3)         
      Solid tumor                                                                          114 (30.9)            79 (33.9)         35 (25.7)         
  History of hematopoietic cell transplantation                                            125 (33.9)            85 (36.5)         40 (29.4)         .17
  Race/ethnicity                                                                                                                                     
      Non-Hispanic white                                                                   141 (38.2)            107 (45.9)        34 (25.0)         .37
      Hispanic                                                                             175 (47.4)            96 (41.2)         79 (58.1)         
      Other/unknown                                                                        53 (14.4)             30 (12.9)         23 (16.9)         
  Median (range) age at diagnosis, years                                                   11 (0-21)             12 (0-21)         9 (0-21)          .13
  Median (range) age at study entry, years                                                 24 (5-57)             24 (5-57)         22 (5-53)         .46
  Median (range) time from diagnosis to study entry, years                                 10.6 (2.8-55.8)       10.0 (3.1-55.8)   11.2 (2.8-40.2)   .44
  Educational level of survey respondent at study entry[\*](#TF1-1){ref-type="table-fn"}                                                             
      Low                                                                                  63 (17.4)             30 (13.0)         33 (25.0)         .002
      Appropriate                                                                          187 (51.5)            117 (50.7)        70 (53.0)         
      Exceeds                                                                              113 (31.1)            84 (36.4)         29 (22.0)         
  Monolingual Spanish speaking                                                             30 (8.1)              17 (7.3)          13 (9.6)          .43

Abbreviation: NA, not applicable.

A total of 363 patients had data available about education level. For patients age younger than 20 years who completed the questionnaire independently, low represents below grade level; appropriate, at grade level; and exceeds, above grade level. For patients age 20 years or older who completed the questionnaire independently or whose parents completed the questionnaire, low represents less than a high school graduate education; appropriate, high school graduate or training; and exceeds, college graduate.

Two hundred eighty-three survivors (76.7%) completed the questionnaire independently; 17 (4.6%) completed the questionnaire with parent/caregiver assistance; and the questionnaire was completed by parent/caregiver alone for 69 of the survivors (18.7%). Because the large majority of survivors completed the questionnaire independently, the term survivors is used to generically refer to responses from all questionnaire respondents in this report.

Therapeutic Exposures
---------------------

Of the 369 patients in the cohort, 352 (95.4%) received chemotherapy, 209 (56.6%) received radiation, 336 (91.1%) underwent surgery (including central line insertion), and 125 (33.9%) underwent hematopoietic cell transplantation (HCT) as part of their cancer treatment. At baseline, survivors were able to correctly identify general categories of their therapeutic exposures with a high degree of accuracy (ie, any chemotherapy, 98.3%; any radiation, 98.6%; any surgery, 83.8%; HCT, 98.4%). Survivors\' abilities to identify these broad categories of therapeutic exposures did not change significantly at subsequent LTFU clinic visits.

Health Risks
------------

The cohort was at risk for a median of six (range, one to nine) of the nine late complications evaluated in this study. (The proportion of patients at risk for each complication by clinic visit is presented in the Data Supplement.) All patients were at risk for at least one complication; 10% were at-risk for 3 or fewer; 66%, for four to eight; and 24%, for all nine complications ([Fig 1](#F1){ref-type="fig"}; Data Supplement).
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Awareness of Personal Health Risks
----------------------------------

Seventy percent of the patients were seen primarily by a nurse practitioner, and 30%, by a physician. Survivors\' awareness of their risk for therapy-related complications improved after three clinic visits ([Fig 2](#F2){ref-type="fig"}). At baseline, awareness ranged from a low of 25% for renal dysfunction to a high of 63% for fertility problems; after three clinic visits, awareness remained lowest (35%) for renal dysfunction and highest (82%) for fertility problems. The largest net gain in awareness was for neurocognitive impairment (44% awareness at baseline; 81%, after three visits), whereas the smallest net gain in awareness was for renal dysfunction (10%).

![Awareness of personal health risks by complication type at study entry and after three education sessions. SMN, subsequent malignant neoplasm.](zlj9991055980002){#F2}

By using generalized estimating equations with adjustment for primary cancer diagnosis, history of HCT, race/ethnicity, and patient/parental educational level, we found that overall awareness of personal health risks (ie, proportion of personal risk correctly identified for all at-risk complications) increased from 38.6% at T0 to 66.4% at T3 ([Fig 3](#F3){ref-type="fig"}). There was a significant gain in awareness from T0 to T1 (*P* \< .001), T1 to T2 (*P* = .03), and T2 to T3 (*P* \< .001), but no significant gain occurred thereafter through T5 (*P* = .7). When the analysis was limited to patients who completed all study time points (n = 88), the trajectory of increasing awareness was similar (Data Supplement). Although 42% of survivors at baseline had no or minimal (\< 25%) awareness of their personal health risks, and although only 14% of survivors at baseline were aware of all or nearly all (\> 75%) of their personal health risks, only 13% of survivors had no or minimal awareness after three educational sessions, and 40% of survivors were aware of all or nearly all of their personal health risks after three educational sessions (Data Supplement).

![Trajectory of awareness of personal risk for late complications by number of education sessions. GEE, generalized estimating equations; HCT, hematopoietic cell transplantation.](zlj9991055980003){#F3}

Trajectory of Awareness of Personal Health Risks
------------------------------------------------

Survivors in the lowest tertile of awareness at T0 demonstrated a steeper gain in awareness over time compared with survivors in the higher tertiles of awareness (*P* \< .001; [Fig 4](#F4){ref-type="fig"}). Change in awareness did not significantly differ by clinician type (physician *v* nurse practitioner; *P* = .66; Data Supplement).

![Awareness of personal risk for late complications by tertile.](zlj9991055980004){#F4}

Predictors for Lowest Tertile of Awareness of Personal Health Risks
-------------------------------------------------------------------

In a multivariable logistic regression model adjusted for respondent type (patient *v* parent/caregiver) and history of HCT (yes/no), factors significantly associated with being in the lowest tertile of awareness at baseline included lower educational level (ie, less than high school graduate if age 20 years or older, or below grade level if age \< 20 years; odds ratio \[OR\], 1.9; 95% CI, 1.2 to 3.4; *P* = .02), longer time from diagnosis (OR, 1.03/year; 95% CI, 1.0 to 1.06; *P* = .04), diagnosis of leukemia (OR, 2.1; 95% CI, 1.2 to 3.1; *P* = .004; referent group: solid tumors and lymphoma), nonwhite race (OR, 2.8; 95% CI, 1.6 to 4.5; *P* \< .001); and at risk for six or fewer complications (OR, 2.1; 95% CI, 1.3 to 3.4, *P* = .002).

DISCUSSION
==========

In this cohort of survivors of childhood cancer who attended a specialized LTFU clinic, in which each survivor received clinician-delivered education tailored to their specific risk of therapy-related complications, we found that survivors\' awareness of personal health risks significantly increased after each of the first three consecutive clinic visits and plateaued thereafter. To our knowledge, this is the first study to evaluate childhood cancer survivors\' changes in awareness about their personal health risks over time.

Consistent with previous studies,^[@B36],[@B48],[@B49]^ survivors in our cohort were able to identify their therapeutic exposures within broad categories (ie, chemotherapy, radiation, surgery, transplantation) with a high degree of accuracy at study entry; we found no significant change in survivors\' awareness about their exposures after receipt of tailored education over multiple time points.

Also consistent with previous studies, we showed that a considerable proportion of survivors of childhood cancer underestimate their risk for therapy-related complications.^[@B48]--[@B51]^ At baseline, our cohort correctly identified only 39% of the complications for which they were at risk, and only 14% of the survivors were aware of all or nearly all (\> 75%) of their personal health risks. Awareness of risk for therapy-related complications improved significantly after three education sessions, such that the cohort could correctly identify 66% of the complications for which they were at risk, and 40% of the survivors were aware of all or nearly all of their personal health risks. However, despite repeatedly receiving tailored education in a specialized survivorship program, fully 60% of survivors failed to achieve awareness of greater than 75% of the complications for which they were at risk.

Self-awareness of health risks is important, because survivors of childhood cancer need to serve as advocates for their own health across settings within the health care system. As time from diagnosis increases, survivors become less likely to receive cancer-related care.^[@B52],[@B53]^ When survivors enter young adulthood, the vast majority of their medical care is delivered by primary care providers, who are often unfamiliar with therapy-related risks.^[@B53]^ Thus, survivors who lack awareness of their personal health risks may fail to seek and receive the appropriate risk-directed follow-up care necessary for prevention and early detection of late-onset therapy-related complications.^[@B25],[@B26],[@B29],[@B54]--[@B58]^

We found that survivors\' awareness of their specific therapy-related risks was lowest at baseline for renal dysfunction (25%) and low bone mineral density (29%) and highest for fertility problems (63%). The largest net gain in awareness after three clinic visits was for neurocognitive impairment (37% net gain); awareness also increased similarly for pulmonary dysfunction (34% net gain), cardiac dysfunction and sensory impairment (33% net gain for each), and low bone mineral density (30% net gain). It is possible that screening tests for these complications (eg, neurocognitive testing, pulmonary function tests, echocardiograms, visual acuity testing, audiograms, and dual energy x-ray absorptiometry scans) may have served to raise awareness and improve recall of risk for these complications beyond the awareness gained through targeted education, whereas some complications for which the net gain in awareness was lower (ie, renal dysfunction and thyroid dysfunction) had associated screening tests (ie, laboratory testing) that may have been less memorable to the survivors. The net gain in awareness for fertility problems was also low (19%). However, because baseline awareness about fertility problems was already high, the lower gain in awareness may represent a ceiling effect. It is also possible that clinicians placed more emphasis on some complications than others and that certain complications may seem more relevant to life concerns of the predominantly young adult survivor population evaluated in this study (eg, fertility and its implications for intimate relationships and family planning,^[@B16],[@B17],[@B59]^ heart/lung function and its association with the ability to participate in recreational activities that require physical exertion,^[@B5],[@B6],[@B60]^ neurocognitive function and its relationship to academic and occupational success^[@B13]--[@B15],[@B59]^).

We found that certain subpopulations were at particular risk of being in the lowest tertile of awareness at study entry. These included survivors who were farther from diagnosis, were of nonwhite race, had lower educational levels, were at risk for six or fewer complications, and had a diagnosis of leukemia. It is possible that survivors from these groups received less information about their therapy-related risks in previous encounters with the health care system, possibly because the health care providers had a lower level of concern about the actual risks (eg, survivors at risk for fewer complications or those with a history of lower-risk leukemia).^[@B54],[@B57],[@B61],[@B62]^ It is also possible that the survivors simply did not understand or recall the information that was provided.^[@B36],[@B48]--[@B51]^ Encouragingly, we found that survivors in the lowest tertile of awareness at baseline derived the most benefit from the educational sessions, as evidenced by their steeper gain in awareness over time.

Strengths of the study include the prospective design, the size and heterogeneity of the cohort, the availability of detailed medical records that allowed identification of risk profiles for individual survivors, the measurement of change in survivors\' awareness of therapy-related health risks over time, and the strategy that provided for a full year between provision of education and each subsequent measurement, which allowed for the first time evaluation of long-term retention of risk awareness in survivors. Enduring acquisition of risk awareness by the survivors is substantiated by the fact that, although there was no additional increase in awareness after three clinic visits, awareness remained stable and did not decline over time.

The findings in this study need to be considered in the context of its limitations. The education was clinician delivered, and, although standardized materials were prepared for each patient, it is possible that there was variability among clinicians in the way that the educational content was presented to patients. To account for this, we looked at differences in awareness over time on the basis of the patient\'s primary clinician type (nurse practitioner *v* physician) and found no statistically significant differences. Finally, this study represents a single-institution experience in a specialized LTFU program for survivors of childhood cancer. The results are possibly not generalizable to survivors of childhood cancer observed at other specialized programs; however, use of the COG-LTFU Guidelines did standardize the education provided in the visits.

These limitations notwithstanding, we found that awareness of personal risk for long-term complications improved after each of three clinician-delivered tailored educational sessions and stabilized thereafter, with no additional improvement or decline. Although overall awareness of personal health risks improved from 39% to 66% over time, fully 60% of the survivors remained unaware of most (\> 75%) of their personal therapy-related health risks despite repeated provision of tailored, personalized health education in a specialized LTFU program. Future studies, therefore, are needed to determine ways to improve uptake of childhood cancer survivors\' awareness of their therapy-related health risks, particularly for the vulnerable subpopulations most likely to lack awareness.

Supplementary Material
======================

###### Data Supplement

See accompanying editorial on page 3849
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